These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 32613672)

  • 1. Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues.
    Liu S; Liu Z; Li W; Zhou B; Liang X; Fan R; Deng R; Hou J; Sun J
    Aliment Pharmacol Ther; 2020 Aug; 52(4):692-700. PubMed ID: 32613672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
    Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
    Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy.
    Wang ML; Chen EQ; Tao CM; Zhou TY; Liao J; Zhang DM; Wang J; Tang H
    Scand J Gastroenterol; 2017 Dec; 52(12):1420-1426. PubMed ID: 28880694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
    Mak LY; Cloherty G; Wong DK; Gersch J; Seto WK; Fung J; Yuen MF
    Hepatology; 2021 Jun; 73(6):2167-2179. PubMed ID: 33159329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2.
    Agarwal K; Buti M; van Bömmel F; Lampertico P; Janczewska E; Bourliere M; Vanwolleghem T; Lenz O; Verbinnen T; Kakuda TN; Mayer C; Jezorwski J; Muenz D; Beumont M; Kalmeijer R; Biermer M; Lonjon-Domanec I
    J Hepatol; 2024 Sep; 81(3):404-414. PubMed ID: 38583491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.
    He D; Guo S; Chen W; Chen X; Yan G; Wang J; Li M; Zhu P; Huang H; Wang Y
    BMC Infect Dis; 2013 Oct; 13():458. PubMed ID: 24090287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
    Wang Y; Liao H; Deng Z; Liu Y; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Duan Z; Lu F; Zheng S
    J Viral Hepat; 2022 Jun; 29(6):420-431. PubMed ID: 35274400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    Papatheodoridis GV
    Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.
    Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Gastroenterol; 2013 Aug; 48(8):930-41. PubMed ID: 23065021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues.
    Luo H; Tan N; Kang Q; Pan J; Chen H; Xi H; Yu M; Xu X
    J Viral Hepat; 2020 Mar; 27(3):323-328. PubMed ID: 31667945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
    Chevaliez S; Hézode C; Bahrami S; Grare M; Pawlotsky JM
    J Hepatol; 2013 Apr; 58(4):676-83. PubMed ID: 23219442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
    Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
    Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
    García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
    J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.
    Liao H; Liu Y; Li X; Wang J; Chen X; Zou J; Li Q; Liu L; Wang J; Huang B; Lu F; Xu D
    Antivir Ther; 2019; 24(2):105-115. PubMed ID: 30511941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
    J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.